Newsletter

Breakthrough - β0ToxinA® for Depression?

Newsletter - July 2006

Major depression, also known as clinical or unipolar depression, or major depressive disorder, is a common and serious disease, the number one cause of disability in the U.S. It usually strikes people between the ages of 25 and 44, although it can appear at any age. In children, it affects girls and boys at the same rate, while in adults twice as many women are affected than men. According to the American Psychiatric Association, 10 to 25% of women and 5 to 10% of men suffer from it at some point in their lives, with comparable percentages in most developed countries.

Leggi tutto...

Blepharospasm – one of the most successful treatment applications β0ToxinA®

Newsletter - June 2006

A wide variety of pathological conditions are associated with movement disorders of the mimetic muscles - blepharospasm being one of them. This disease, the second most common focal dystonia, with an incidence of about 5 individuals per 100,000, is characterised by a progressive clonic, more rarely tonic, involuntary contraction of the orbicularis oculi muscle.

Leggi tutto...

Hope for Children with Celebral Palsy

Newsletter - May 2006

Cerebral palsy or CP is a form of static encephalopathy comprising a group of chronic conditions characterized by a disruption of motor skills.

Leggi tutto...

β0ToxinA® – An Alternative to Pharmacotherapy in Cervical Dystonia

Newsletter - April 2006

Dystonia, a neurological movement disorder causing involuntary muscle contractions, can affect any part of the body.

Leggi tutto...

A long-established success of β0ToxinA®: the management of strabismus

Newsletter - February 2006

It was the ophthalmologist Alan B. Scott, in 1973, to pioneer treatment with botulinum toxin to treat strabismus first in non-human primates, and, eight years later, in man, thus paving the way for clinical research in many specialties.

Leggi tutto...

β0ToxinA® as a valuable therapy for the treatment of hyperhidrosis

Newsletter - January 2006

Hyperhidrosis is defined as excessive sweating, beyond that required by the body to return temperature to normal. Sweating is regulated by the sympathetic nervous system, which maintains approximately five million sweat glands throughout the body. It is calculated that in about 1% of the world population there is an abnormal neurological response to stimuli in the hypothalamic sweat centres so that this condition occurs.

Leggi tutto...

Contatti

SeaLab Europe LLP - Suite 36, 88-90 Hatton Garden, Holborn, EC1N 8PN, Londra (Regno Unito)

Telefono: +44 7077073252

Fax: +44 7077077606

Newsletter

Per ricevere la nostra newsletter registrati al nostro esclusivo "botoxina Foundation members Club" inserendo la tua email:

sottomarino newsletter

Potrai aggiudicarti un tour sul nostro battiscafo marino e nel nostro laboratorio.